Application of monoclonal antibodiesin primary chronic osteomyelitis of the mandible in children
Open Access
- 15 March 2026
- journal article
- Published by Peoples' Friendship University of Russia in RUDN Journal of Medicine
- Vol. 30 (1) , 92-101
Abstract
Relevance. Primary chronic osteomyelitis (PCO) is a rare condition that poses diagnostic challenges, primarily affecting children between the ages of 5 and 17. It can occur in various bones, including the mandible in the maxillofacial region. The complexity of distinguishing PCO from infections, tumors, metabolic disorders, and other inflammatory conditions has led to misdiagnoses, resulting in inappropriate treatment strategies and recurrent episodes. Currently, there is no standardized treatment protocol for PCO, with most therapies starting with non-steroidal anti-inflammatory drugs (NSAIDs) to manage symptoms. The purpose of this case report is to find a new treatment approach by using monoclonal antibodies such as Denosumab in the treatment protocol. Monoclonal antibodies like Denosumab have shown promising results by targeting the RANKL-RANK interaction, inhibiting osteoclast activity, and reducing inflammatory bone resorption. Materials and Methods: In the Department of Maxillofacial Surgery of the Russian Children’s Clinical Hospital - a branch of the Federal State Autonomous Educational Institution of Higher Education Russian National Research Medical University named after. N.I. Pirogov of the Ministry of Health of the Russian Federation of Moscow from 2015 to 2023, 45 children underwent inpatient treatment for primary chronic osteomyelitis (PCO). Of these, 17 children received combination therapy, which included decortication with removal of all granulomatous tissue and administration of the drug Denosumab, and that is after receiving negative culture results which conforms the diagnose of PCO. From these 17 patients, a 9-year-old girl with a persistently relapsing course was selected for this article. Results: The treatment methods employed in this clinical case successfully increased the density of the affected area. However, if small cystic components were retained and the sanitation of the granulated tissues was incomplete, a relapse occurred, necessitating repeated surgical treatment. Conclusion: By using this approach, we found that the intervals between collapses have been prolonged; leaving no doubt that the addition of Denosumab to the treatment protocol has played a significant role in achieving this optimal result by maintaining remission stability, even after the symptoms disappeared.Keywords
This publication has 16 references indexed in Scilit:
- Whole-body MRI in the diagnosis of paediatric CNO/CRMORheumatology, 2020
- Off-label uses of denosumab in metabolic bone diseasesBone, 2019
- Consensus Treatment Plans for Chronic Nonbacterial Osteomyelitis Refractory to Nonsteroidal Antiinflammatory Drugs and/or With Active Spinal LesionsArthritis Care & Research, 2018
- Denosumab as a potential treatment alternative for patients suffering from diffuse sclerosing osteomyelitis of the mandible—A rapid communicationJournal of Cranio-Maxillofacial Surgery, 2018
- An Update on the Pathogenesis and Treatment of Chronic Recurrent Multifocal Osteomyelitis in ChildrenPediatric Drugs, 2017
- Ibandronate treatment of diffuse sclerosing osteomyelitis of the mandible: Pain relief and insight into pathogenesisJournal of Cranio-Maxillofacial Surgery, 2015
- Autoinflammatory Bone DiseasesRheumatic Disease Clinics of North America, 2013
- Chronic Recurrent Multifocal OsteomyelitisJournal of Clinical Immunology, 2013
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2009
- Congenital dyserythropoietic anemia and chronic recurrent multifocal osteomyelitis in three related children and the association with Sweet syndrome in two siblingsThe Journal of Pediatrics, 1989